UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.824

Sortiert nach

Degradation of misfolded proteins in neurodegenerative diseases: therapeutic targets and strategies

Experimental & molecular medicine, 2015-03, Vol.47 (3), p.e147-e147

2015

Volltextzugriff (PDF)

Benefits of curcumin in brain disorders

BioFactors (Oxford), 2019-09, Vol.45 (5), p.666-689

2019

Volltextzugriff (PDF)

Ferrostatins Inhibit Oxidative Lipid Damage and Cell Death in Diverse Disease Models

Journal of the American Chemical Society, 2014-03, Vol.136 (12), p.4551-4556

2014

Volltextzugriff (PDF)

Biological metals and metal-targeting compounds in major neurodegenerative diseases

Chemical Society reviews, 2014-01, Vol.43 (19), p.6727-6749

2014

Volltextzugriff (PDF)

The Role of Reactive Oxygen Species in the Pathogenesis of Alzheimer’s Disease, Parkinson’s Disease, and Huntington’s Disease: A Mini Review

Oxidative medicine and cellular longevity, 2016-01, Vol.2016 (1), p.8590578-8590578

2016

Volltextzugriff (PDF)

PPARγ as a therapeutic target to rescue mitochondrial function in neurological disease

Free radical biology & medicine, 2016-11, Vol.100, p.153-163

2016

Volltextzugriff (PDF)

Multiple roles of HDAC inhibition in neurodegenerative conditions

Trends in neurosciences (Regular ed.), 2009-11, Vol.32 (11), p.591-601

2009

Volltextzugriff (PDF)

Potential therapeutic uses of BDNF in neurological and psychiatric disorders

Nature reviews. Drug discovery, 2011-03, Vol.10 (3), p.209-219

2011

Volltextzugriff (PDF)

The Potential of Flavonoids for the Treatment of Neurodegenerative Diseases

International journal of molecular sciences, 2019-06, Vol.20 (12), p.3056

Maher, Pamela

2019

Volltextzugriff (PDF)

Selenium Nanoparticles as an Efficient Nanomedicine for the Therapy of Huntington’s Disease

ACS applied materials & interfaces, 2019-09, Vol.11 (38), p.34725-34735

2019

Volltextzugriff (PDF)

Small molecule splicing modifiers with systemic HTT-lowering activity

Nature communications, 2021-12, Vol.12 (1), p.7299-7299, Article 7299

2021

Volltextzugriff (PDF)

Dysregulation of glutathione homeostasis in neurodegenerative diseases

Nutrients, 2012-10, Vol.4 (10), p.1399-1440

2012

Volltextzugriff (PDF)

Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study

Lancet neurology, 2019-02, Vol.18 (2), p.165-176

2019

Volltextzugriff (PDF)

Linking lipid peroxidation and neuropsychiatric disorders: focus on 4-hydroxy-2-nonenal

Free radical biology & medicine, 2017-10, Vol.111, p.281-293

2017

Volltextzugriff (PDF)

An orally available, brain penetrant, small molecule lowers huntingtin levels by enhancing pseudoexon inclusion

Nature communications, 2022-03, Vol.13 (1), p.1150-1150, Article 1150

2022

Volltextzugriff (PDF)

Antisense therapies for movement disorders

Movement disorders, 2019-08, Vol.34 (8), p.1112-1119

2019

Volltextzugriff (PDF)

Suppression of Somatic Expansion Delays the Onset of Pathophysiology in a Mouse Model of Huntington's Disease

PLoS genetics, 2015-08, Vol.11 (8), p.e1005267

2015

Volltextzugriff (PDF)

An MDS Evidence‐Based Review on Treatments for Huntington's Disease

Movement disorders, 2022-01, Vol.37 (1), p.25-35

2022

Volltextzugriff (PDF)

Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial

Lancet neurology, 2015-01, Vol.14 (1), p.39-47

Anon

2015

Volltextzugriff (PDF)

Multi-target-Directed Ligands To Combat Neurodegenerative Diseases

Journal of medicinal chemistry, 2008-02, Vol.51 (3), p.347-372

2008

Volltextzugriff (PDF)

Inhibition of mitochondrial fragmentation diminishes Huntington's disease-associated neurodegeneration

The Journal of clinical investigation, 2013-12, Vol.123 (12), p.5371-5388

2013

Volltextzugriff (PDF)

Mitochondrial superoxide generation induces a parkinsonian phenotype in zebrafish and huntingtin aggregation in human cells

Free radical biology & medicine, 2019-01, Vol.130, p.318-327

2019

Volltextzugriff (PDF)

Enriched chitosan nanoparticles loaded with siRNA are effective in lowering Huntington's disease gene expression following intranasal administration

Nanomedicine, 2020-02, Vol.24, p.102119-102119, Article 102119

2020

Volltextzugriff (PDF)

Dopamine depleters in the treatment of hyperkinetic movement disorders

Expert opinion on pharmacotherapy, 2016-12, Vol.17 (18), p.2461-2470

Jankovic, Joseph

2016

Volltextzugriff (PDF)

An alternative splicing modulator decreases mutant HTT and improves the molecular fingerprint in Huntington's disease patient neurons

Nature communications, 2022-11, Vol.13 (1), p.6797-14, Article 6797

2022

Volltextzugriff (PDF)

1 – 25 von 1.824

Suche als RSS-Feed

Aktive Filter

KollektionSingle Journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.632)
Mit Volltextzugriff
(1.342)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

12 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(1.502)
Life Sciences & Biomedicine
(1.430)
Humans
(1.364)
Huntington Disease - Drug Therapy
(1.092)
Animals
(932)
Neurosciences & Neurology
(771)
Huntington's Disease
(768)
Neurosciences
(616)
Male
(603)
Female
(440)
Disease Models, Animal
(426)
Pharmacology & Pharmacy
(390)
Neurology
(355)
Mice
(337)
Huntington Disease - Metabolism
(333)
Huntington Disease - Genetics
(310)
Clinical Neurology
(303)
Middle Aged
(303)
Adult
(289)
Huntingtons Disease
(284)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Movement Disorders
(63)
Plos One
(44)
Journal Of Huntington's Disease
(41)
Neurobiology Of Disease
(35)
International Journal Of Molecular Sciences
(33)
Experimental Neurology
(28)
Clinical Neuropharmacology
(23)
Molecular Neurobiology
(22)
Lancet Neurology
(19)
Neurotherapeutics
(18)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Degradation of misfolded proteins in neurodegenerative diseases: therapeutic targets and strategies

Benefits of curcumin in brain disorders

Ferrostatins Inhibit Oxidative Lipid Damage and Cell Death in Diverse Disease Models

Biological metals and metal-targeting compounds in major neurodegenerative diseases

The Role of Reactive Oxygen Species in the Pathogenesis of Alzheimer’s Disease, Parkinson’s Disease, and Huntington’s Disease: A Mini Review

PPARγ as a therapeutic target to rescue mitochondrial function in neurological disease

Multiple roles of HDAC inhibition in neurodegenerative conditions

Potential therapeutic uses of BDNF in neurological and psychiatric disorders

The Potential of Flavonoids for the Treatment of Neurodegenerative Diseases

Selenium Nanoparticles as an Efficient Nanomedicine for the Therapy of Huntington’s Disease

Small molecule splicing modifiers with systemic HTT-lowering activity

Dysregulation of glutathione homeostasis in neurodegenerative diseases

Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study

Linking lipid peroxidation and neuropsychiatric disorders: focus on 4-hydroxy-2-nonenal

An orally available, brain penetrant, small molecule lowers huntingtin levels by enhancing pseudoexon inclusion

Antisense therapies for movement disorders

Suppression of Somatic Expansion Delays the Onset of Pathophysiology in a Mouse Model of Huntington's Disease

An MDS Evidence‐Based Review on Treatments for Huntington's Disease

Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial

Multi-target-Directed Ligands To Combat Neurodegenerative Diseases

Inhibition of mitochondrial fragmentation diminishes Huntington's disease-associated neurodegeneration

Mitochondrial superoxide generation induces a parkinsonian phenotype in zebrafish and huntingtin aggregation in human cells

Enriched chitosan nanoparticles loaded with siRNA are effective in lowering Huntington's disease gene expression following intranasal administration

Dopamine depleters in the treatment of hyperkinetic movement disorders

An alternative splicing modulator decreases mutant HTT and improves the molecular fingerprint in Huntington's disease patient neurons

Aktive Filter

Suchergebnisse filtern